Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig in High Risk Locally Advanced Cervical Cancer
NCT06943833Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volrustomig in Cervical Cancer (CC), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 36 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06943833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943833.